J. Nadal

High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patients

M. Rizzo, M. Roberti, E. Levy, 2018, OncoTargets and therapy.

High Histologic Grade and High Ki-67 Expression Predict Phenotypic Alterations in Node Metastasis in Primary Breast Cancers

M. Rizzo, Mora Amat, J. Loza, 2017, Journal of breast cancer.

Predictive Factors for Non-Sentinel Lymph Node Metastasis in Patients with ACOSOG Z0011 Criteria

R. Chacón, J. Loza, F. Coló, 2018, Breast Care.

Sternal metastasis of breast cancer: ex vivo hypothermia and reimplantation.

J. Nadal, A. Patané, A. Rosales, 2011, The Annals of thoracic surgery.

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.

M. Burotto, L. Fallowfield, S. Margolin, 2021, European journal of cancer.

Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair–Related Genes

R. Chacón, Mora Amat, F. Coló, 2022, JCO precision oncology.

Axillary recurrence after sentinel node biopsy for operable breast cancer.

R. Chacón, J. Loza, F. Coló, 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Breast Cancer in Young Women Presents With More Aggressive Pathologic Characteristics: Retrospective Analysis From an Argentine National Database

M. Rizzo, R. Chacón, D. Mysler, 2020, JCO global oncology.

Small seeds for big debates:: Past and present contributions to Palaeoart studies from North-eastern Iberia

M. García-Diez, J. Fullola, J. Nadal, 2015 .

LBA18 Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial

H. Denys, S. Tolaney, J. Nadal, 2022, Annals of Oncology.

Cardiotoxicity Alerts during Treatment with Trastuzumab in Breast Cancer at Four-year Follow-up

R. Chacón, C. Chacon, D. Santos, 2019 .

Less efficacy with alternating regimen as adjuvant chemotherapy in stage II node-positive breast cancer: results at 8 years (Pronacam 85).

M. Bader, C. Albera, A. Romero, 1997, British Journal of Cancer.